CSV November 24, 2022 through November 24, 2024 All Errata for USP–NF How to use

×

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
    - For example, a search on Aminosalicylic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
    - A search for “Aminosalicylic Acid Tablets” will result in anything that specifically contains “Aminosalicylic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
    - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:**You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
PHARMACEU	19. MEAN	*USP42–NF37*	7831	26-Apr-2019	1-May-2019	*NA*	*NA*	In the variable

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
TICAL CALCULATIONS IN PHARMACY PRACTICE	KINETIC TEMPERATURE/*19.2 MKT Equation*							definition list: Change T_n = value for the total number of storage temperatures recorded during the observation period temperature recorded during the nth time period, e.g., *n*th week to: T_n = value for the temperature recorded during the *n*th time period, e.g., *n*th week
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE TABLETS	ASSAY/*Procedure/Chromatographic system*	*First Supplement to USP42–NF37*	Online	26-Apr-2019	1-May-2019	*NA*	*NA*	In *Column*: Change 4.6-mm × 15-cm; 5-µm packing L7. [Note—Conditioning of the *Column* with *Solution A* and *Solution B* $^{?}(90:10)_{?}$ (ERR

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								1-Mar-2019) for about 30 min is recommended prior to use.] to: 4.6-mm × 15-cm; 5-µm packing L7
IMIPRAMINE PAMOATE CAPSULES	IM PUR ITIES/*Organic Impurities*	*USP42–NF37*	Online	26-Apr-2019	1-May-2019	*NA*	*NA*	In *Solution A*: Change *Chromatographic acetonitrile* to: Acetonitrile AND In *Solution B*: Change *chromatographic acetonitrile* to: acetonitrile
MORPHINE SULFATE EXTENDED-RELEASE CAPSULES	IM PUR ITIES/*Organic Impurities*	*Revision Bulletin (Official November 01, 2018)*	Online	26-Apr-2019	1-May-2019	*NA*	*NA*	In Row 4 of Column 1 of *Table 5*: Change Morphine related compound B[b] to: Morphine related

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								compound B (anhydrous)[b]
HYPROMELLOSE PHTHALATE	IMPURITIES/*Chloride and Sulfate <221>, Chloride*	*Harmonization (Official May 01, 2019)*	Online	26-Apr-2019	1-May-2019	*NA*	*NA*	In *Analysis*: Change [?]Add 1 mL of silver nitrate TS to the *Standard solution* and then add a 50-mL portion of the *Sample solution*. Mix and allow to stand for 5 min protected from direct sunlight. Compare the turbidity of the solutions.?(NF 1-May-2019) to: Add 1 mL of silver nitrate TS to the *Standard solution*. Add 1 mL of silver nitrate TS to a 50-mL portion of the *Sample solution*. After mixing, allow

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								each solution to stand for 5 min protected from direct sunlight. Compare the turbidity of the solutions.
NEPHELOMETRY AND TURBIDIMETRY	5. FORMAZIN TURBIDITY STANDARDS	*USP42–NF37*	7059	26-Apr-2019	1-May-2019	*NA*	*NA*	In paragraph 1: Change *IUPAC Compendium of Chemical Technology,* to: *IUPAC Compendium of Chemical Terminology,*
FELODIPINE EXTENDED-RELEASE TABLETS	PERFORMANCE TESTS/ *Dissolution <711>/Test 2*	*USP42–NF37*	1787	26-Apr-2019	1-May-2019	*NA*	*NA*	In the second variable definition list in *Analysis*: Change V_S = volume of the *Sample solution* withdrawn at each time point, *i* to: *V*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								s= volume of the *Sample solution* withdrawn at each time point, *i* (mL)
LEVALBUTEROL INHALATION SOLUTION	IMPURITIES/*Organic Impurities*	*USP42–NF37*	2520	26-Apr-2019	1-May-2019	*NA*	*NA*	In Row 3 of *Table 3*: Change Levalbuterol — — — to: Levalbuterol 1.0 — —
THALIDOMIDE	*Assay*	*USP42–NF37*	4281	26-Apr-2019	1-May-2019	*NA*	*NA*	In *Chromatographic system*: Change and the relative standard deviation for replicate injections is not more than 1.0%. to: and the relative standard deviation for the response ratio of thalidomide

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to phenacetin is not more than 1.0%.
REAGENTS AND REFERENCE TABLES	REAGENT SPECIFICATIONS	*USP42–NF37*	6104	26-Apr-2019	1-May-2019	*NA*	*NA*	In *Ferric Nitrate*: Change [10421-48-4]. to: [7782-61-8].
PSEUDOEPHEDRINE HYDROCHLORIDE EXTENDED-RELEASE TABLETS	PERFORMANCE TESTS/ *Dissolution <711>*	*Revision Bulletin (Official March 01, 2019)*	Online	26-Apr-2019	1-May-2019	*NA*	*NA*	In the *Figure 1* caption: Change (see *Drug Release <724>, Figure 4c*) to: (see *Drug Release <724>, Figure 5c*)
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE TABLETS	PERFORMANCE TESTS/ *Dissolution <711>*	*First Supplement to USP42–NF37*	Online	26-Apr-2019	1-May-2019	*NA*	*NA*	In Row 2 of Column 3 of *Table 4*: Change $0.014^{?}/0.028_{?2S}$ *(USP41)* to: 0.014 AND In Row 3 of Column 3 of *Table 4*: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								0.014 to: 0.014/0.028 AND In *Chromatographic system*/*Column*: Change 4.6-mm × 15-cm; 5-µm packing L7. [Note—Conditioning of the *Column* with *Solution A* and *Solution B* (80:20) for NLT 20 min is recommended prior to use.] to: 4.6-mm × 15-cm; 5-µm packing L7
LEVALBUTEROL HYDROCHLORIDE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP42–NF37*	2518	26-Apr-2019	1-May-2019	*NA*	*NA*	In USP Levalbuterol Related Compound D RS: Change 5-{2-[(1,1-Dimethylethyl)amino]-

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								1-hydroxyethyl}-2-hydroxy-benzaldehyde. $C_{13}H_{19}NO_3$ 237.29 ?[NOTE—This may be available as the sulfate salt (2:1).]? (USP 1-May-2019)
								to: 5-[2-(*tert*-Butylamino)-1-hydroxyethyl]-2-hydroxybenzaldehyde sulfate (2:1) (salt); Also known as 5-[2-{(1,1-Dimethylethyl)amino}-1-hydroxyethyl]-2-hydroxy-benzaldehyde sulfate (2:1). $(C_{13}H_{19}NO_3)_2 \cdot H_2SO_4$ 572.67
MORPHINE SULFATE EXTENDED-RELEASE	ADDITIONAL REQUIREMENTS/*USP Reference*	*Revision Bulletin (Official November 01, 2018)*	Online	26-Apr-2019	1-May-2019	*NA*	*NA*	In USP Morphine Related Compound B

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
CAPSULES	*Standards <11>*							RS: Change 2,2'-Bimorphine. $C_{34}H_{36}N_2O_6$ 568.66 to: 2,2'-Bimorphine trihydrate. $C_{34}H_{36}N_2O_6$? $3H_2O$ 622.72
INOSITOL	IM PURITIES/*Limit of Lead*	*USP42–NF37*	5776	26-Apr-2019	1-May-2019	*NA*	*NA*	In *Standard lead solution*: Delete A comparison solution prepared on the basis of 100 µL of the *Standard lead solution* per g of substance being tested contains the equivalent of 1 part of lead per million parts of substance being tested.
PHARMACEUTICAL CALCULATIONS IN PHARMACY	10. ALLIGATION ALTERNATE AND ALGEBRA	*USP42–NF37*	7831	26-Apr-2019	1-May-2019	*NA*	*NA*	In *10.2 Algebra Method*/*10.2.1 Calculating by using the*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
PRACTICE	METHODS FOR COMBINING MULTIPLE STRENGTHS OF THE SAME ACTIVE PHAR MACEUTICAL INGREDIENT							*algebra method/ Examples—Alge bra method*: In example *2*, in equations 1, 2, 3, and 4 in all instances: Change C_s to: Q_s AND In example 2, in equation 5: Change C_w to: Q_w
ATORVASTATIN CALCIUM	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP42–NF37*	410	26-Apr-2019	1-May-2019	*NA*	*NA*	In USP Atorvastatin Related Compound A RS: Change Desfluoro impurity, or (3*R*,5*R*)-7-[3-(phenylcarbamoyl)-2-isopropyl-4,5-diphenyl-1*H*-pyrrol-1-yl]-3,5-

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								dihydroxyhepta noic acid, calcium salt. to: Calcium (3*R*,5*R*)-7-[2-isopropyl-4,5-diphenyl-3-(phenylcarbamo yl)-1*H* -pyrrol-1-yl]-3,5-dihydroxyhepta noate (1:2); Also known as Desfluoro impurity, or (3*R*,5*R*)-7-[3-(phenylca rbamoyl)-2-isop ropyl-4,5-diphen yl-1*H* -pyrrol-1-yl]-3,5-dihydroxyhepta noic acid, calcium salt.
IMIPRAMINE PAMOATE CAPSULES	ASSAY/ *Procedure*	*USP42–NF37*	Online	26-Apr-2019	1-May-2019	*NA*	*NA*	In *Solution A* and *Solution B* and *Diluent*: Change *Chromatographic acetonitrile*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
LEVALBUTEROL INHALATION SOLUTION	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP42–NF37*	2520	26-Apr-2019	1-May-2019	*NA*	*NA*	to: Acetonitrile In USP Levalbuterol Related Compound D RS: Change 5-[2-{(1,1-Dimethylethyl)amino}-1-hydroxyethyl]-2-hydroxy-benzaldehyde; Also known as 5-[2-{(1,1-Dimethylethyl)amino}methyl]-4-hydroxy-3-(methoxymethyl)-benzene methanol. $C_{13}H_{19}NO_3$ 237.29 [NOTE: This Reference Standard is available as the benzesulfonic acid salt.] to: 5-[2-(*tert*-Butylamino)-1-hydroxyethyl]-2-

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								hydroxybenzaldehyde sulfate (2:1) (salt); Also known as 5-[2-{(1,1-Dimethylethyl)amino}-1-hydroxyethyl]-2-hydroxy-benzaldehyde sulfate (2:1). $(C_{13}H_{19}NO_3)_2 \cdot H_2SO_4$ 572.67
TRAMADOL HYDROCHLORIDE EXTENDED-RELEASE TABLETS	PERFORMANCE TESTS/*Dissolution <711>/Test 1/Instrumental conditions*	*USP42–NF37*	4409	26-Apr-2019	1-May-2019	*NA*	*NA*	In *Cell*: Change 5 cm to: 5 mm
NEPHELOMETRY AND TURBIDIMETRY	4. INSTRUMENTATION	*USP42–NF37*	7059	26-Apr-2019	1-May-2019	*NA*	*NA*	In paragraph 2: Change silicone diodes to: silicon diodes
CLONIDINE TRANSDERMAL SYSTEM	PERFORMANCE TESTS/*Drug Release <724>/Test 1*	*USP42–NF37*	1084	26-Apr-2019	1-May-2019	*NA*	*NA*	*Apparatus 7*: Change (see *Figure 4a*). to: (see *Figure 5a*).
METAXALONE	IDENTIFICATION/*B.*	*USP41–NF36*	2611	29-Mar-2019	1-Apr-2019	*NA*	*NA*	Change The retention

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								time of the major peak of the *Sample solution* corresponds to that of the *Sample solution*, as obtained in the *Assay*. to: The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the *Assay*.
ISOPHANE INSULIN HUMAN SUSPENSION	ASSAY/ *Procedure*	*Interim Revision Announcement (Official January 01, 2019)*	Online	29-Mar-2019	1-Apr-2019	*NA*	*NA*	In *Standard solution*: Change USP Insulin Beef RS to: USP Insulin Human RS
SCOPOLAMIN	IDENTIFICATIO	*First*	8420	29-Mar-2019	1-Apr-2019	*NA*	*NA*	In *Sample*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
E HYDROBROMIDE	N/*B.*	*Supplement to USP41–NF36*						*solution*: Change 50 mg/mL of alcohol to: 50 mg/mL in water
PREDNISOLONE SODIUM PHOSPHATE	*Related compounds*	*USP41–NF36*	3416	29-Mar-2019	1-Apr-2019	*NA*	*NA*	In *Table 1*: Add Prednisolone sodium phosphate 1.00 — —
MERCAPTOPURINE	IMPURITIES/*Organic Impurities*	*USP41–NF36*	2587	29-Mar-2019	1-Apr-2019	*NA*	*NA*	Change *Sample solution*: 0.12 mg/mL of Mercaptopurine in *Solution A*. [NOTE—Inject the *Sample solution* within 1 h of preparation.] to: *Sample stock solution*: 0.5 mg/mL of mercaptopurine in a mixture of methanol and *Solution A* (1:9)

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								prepared as follows. Transfer a suitable quantity of Mercaptopurine to an appropriate volumetric flask, add methanol equivalent to 10% of the final volume, and shake to dissolve. Dilute with *Solution A* to volume. *Sample solution*: 0.12 mg/mL of mercaptopurine in *Solution A* from the *Sample stock solution*. [NOTE—Inject the *Sample solution* within 1 h of preparation.]
BUMETANIDE	ASSAY/	*Second*	Online	29-Mar-2019	1-Apr-2019	*NA*	*NA*	In *Sample*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
TABLETS	*Procedure*	*Supplement to USP41–NF36*						*solution*: Change Nominally 0.05 mg/mL of bumetanide prepared as follows. to: Nominally 125 µg/mL of bumetanide prepared as follows.
RUTIN	CHEMICAL INFORMATION	*USP41–NF36*	4841	29-Mar-2019	1-Apr-2019	*NA*	*NA*	Change 3-Rhamnoglucoside of 5,7,3',4'-tetrahydroxyflavonol; 2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4*H*-chromen-4-one-3-yl 6-*O*-?-L-rhamnopyranosyl-?-D-glucoside [250249-75-3]. to: 3-Rhamnoglucoside of 5,7,3',4'-

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								tetrahydroxyflavonol trihydrate; 2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4*H*-chromen-4-one-3-yl 6-*O*-?-L-rhamnopyranosyl-?-D-glucoside trihydrate [250249-75-3].
ARGATROBAN	CHEMICAL INFORMATION	*USP41–NF36*	346	22-Feb-2019	1-Mar-2019	*NA*	*NA*	See https://www.usp nf.com/sites/def ault/files/usp_pd f/EN/february_2 019_errata_ima ge1.pdf for correction
CALCIUM SILICATE	IM PURITIES/*Limit of Lead*	*USP41–NF36*	5240	22-Feb-2019	1-Mar-2019	*NA*	*NA*	In *Lead standard solution*: Change 1000 mg of lead/mL^{4} to: 1000 mg of lead/L^{4}
CARBINOXAMI	IM	*Second*	8788	22-Feb-2019	1-Mar-2019	*NA*	*NA*	In the *Standard*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
NE MALEATE TABLETS	PUR ITIES/*Organic Impurities*	*Supplement to USP41–NF36*						*stock solution*: Change USP Carbinoxamine Maleate RS free base) to: carbinoxamine) AND In the *Standard solution*: Change USP Carbinoxamine Maleate RS free base) to: carbinoxamine) AND In the *Analysis*: Change C_S = concentration of USP Carbinoxamine Maleate RS free base to: C_S = concentration of USP

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Carbinoxamine Maleate RS (as the free base)
REAGENTS	*Reagent S pec ificatio ns/ 7,8-Dihydrofolic Acid*	*Second Supplement to USP41–NF36*	9052	22-Feb-2019	1-Mar-2019	*NA*	*NA*	Change *(L-Glutamic Acid, N-[4-[[(2-A mino-3,4,7,8-tet rahydro-4-pterid inyl)methyl]amin o]benzoyl]-),* to: *(L-Glutamic Acid, N-[4-[[(2-A mino-3,4,7,8-tet rahydro-4-oxo-6 -pteridinyl)meth yl]amino]benzoy l]-),*
METHYLDOPA	SPECIFIC TESTS/*Optical Rotation <781S>*	*USP41–NF36*	2666	22-Feb-2019	1-Mar-2019	*NA*	*NA*	In the *Sample solution*: Change aluminum chloride to: aluminum chloride hexahydrate
CANDESARTA N CILEXETIL AND HYDROC HLOROTHIAZI	ASSAY/ *Proce dure/ Chromatographi*	*Second Supplement to USP41–NF36*	8781	22-Feb-2019	1-Mar-2019	*NA*	*NA*	In *Column*: Change [Note—Condition ing of the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
DE TABLETS	*c system*							*Column* with *Solution A* and *Solution B* (80:20) to: [Note—Conditioning of the *Column* with *Solution A* and *Solution B* (90:10)
MESNA TABLETS	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*Second Supplement to USP41–NF36*	8906	22-Feb-2019	1-Mar-2019	*NA*	*NA*	In USP Mesna Related Compound A RS: Change 2-(Acetylthio)ethane-1-sulfonic acid. $C_4H_8O_4S_2$ 184.22 to: 2-(Acetylthio)ethane-1-sulfonic acid, potassium salt, crystal adduct with potassium chloride. $C_4H_7KO_4S_2$? KCl 296.86 AND

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
DEXMEDETOMIDINE HYDROCHLORIDE	CHEMICAL INFORMATION	*USP41–NF36*	Online	22-Feb-2019	1-Mar-2019	*NA*	*NA*	In USP Mesna Related Compound B RS: Change 2,2?-Disulfanediylbis(ethane-1-sulfonic acid). $C_4H_{10}O_6S_4$ 282.36 to: 2,2?-Disulfanediylbis(ethane-1-sulfonic acid), dipotassium salt, crystal adduct with sodium chloride. $C_4H_8K_2O_6S_4$? NaCl 416.98 This erratum applies to the *USP-NF* ONLINE platform only. See https://www.usp nf.com/sites/default/files/usp_pdf/EN/february_2019_errata_ima

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								ge1.pdf for correction
REAGENTS	*Solutions/Volumetric Solutions/0.01 N Sodium Hydroxide VS*	*USP41–NF36*	5770	22-Feb-2019	1-Mar-2019	*NA*	*NA*	See https://www.usp nf.com/sites/def ault/files/usp_pd f/EN/february_2 019_errata_ima ge1.pdf for correction
FLUDROCORTISONE ACETATE TABLETS	IMPURITIES/*Organic Impurities/Table 1*	*Second Supplement to USP41–NF36*	8843	22-Feb-2019	1-Mar-2019	*NA*	*NA*	In footnote a: Change 9-Fluoro-11?,17,21-trihydroxypregn-4-ene-3,20-dione 21-acetate. to: 9-Fluoro-11?,17,21-trihydroxypregn-4-ene-3,20-dione.
ANALYTICAL DATA—INTERPRETATION AND TREATMENT	MEASUREMENT PRINCIPLES AND VARIATION	*USP42–NF37*	7129	22-Feb-2019	1-Mar-2019	*NA*	*NA*	See https://www.usp nf.com/sites/def ault/files/usp_pd f/EN/february_2 019_errata_ima ge1.pdf for correction
OXANDROLON	*Related*	*USP41–NF36*	3072	22-Feb-2019	1-Mar-2019	*NA*	*NA*	In footnote 4 of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
E	*compounds*							the second table: Change Methyl-(1,17?-dihydroxy-17?-methyl-1,3-seco-2-nor-5?-androstane-3-oate. to: Methyl 1,17?-dihydroxy-17?-methyl-1,3-seco-2-nor-5?-androstan-3-oate.
CARBINOXAMINE MALEATE	IMPURITIES/*Organic Impurities*	*Second Supplement to USP41–NF36*	8786	22-Feb-2019	1-Mar-2019	*NA*	*NA*	In *Standard stock solution*: Change (equivalent to 0.05 mg/mL of USP Carbinoxamine Maleate RS free base) and 0.05 mg/mL each of USP Carbinoxamine Related Compound A RS, USP Carbinoxamine Related Compound B

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								RS, and USP Carbinoxamine Related Compound C RS free base to: (equivalent to 0.05 mg/mL of carbinoxamine) and 0.05 mg/mL each of USP Carbinoxamine Related Compound A RS, USP Carbinoxamine Related Compound B RS, and USP Carbinoxamine Related Compound C RS (as the free base) AND In the *Standard solution*: Change (equivalent to 0.001 mg/mL of USP

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Carbinoxamine Maleate RS free base) and 0.001 mg/mL each of USP Carbinoxamine Related Compound A RS, USP Carbinoxamine Related Compound B RS, and USP Carbinoxamine Related Compound C RS free base to: (equivalent to 0.001 mg/mL of carbinoxamine) and 0.001 mg/mL each of USP Carbinoxamine Related Compound A RS, USP Carbinoxamine Related Compound B

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								RS, and USP Carbinoxamine Related Compound C RS (as the free base) AND In the *Analysis*: Change C_S = concentration of USP Carbinoxamine Maleate RS free base to: C_S = concentration of USP Carbinoxamine Maleate RS (as the free base)
PRAZOSIN HYDROCHLORIDE COMPOUNDED ORAL SUSPENSION	ASSAY/ *Procedure*	*Second Supplement to USP41–NF36*	8945	22-Feb-2019	1-Mar-2019	*NA*	*NA*	In the *Mobile phase*: Change tetramethylammonium hydrochloride to: tetramethylammonium hydroxide

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
DIVALPROEX SODIUM EXTENDED-RELEASE TABLETS	ASSAY/*Procedure*	*USP41–NF36*	1358	22-Feb-2019	1-Mar-2019	*NA*	*NA*	In *Buffer*: Change 0.5 g/L of citric acid and 0.4 g/L of dibasic sodium phosphate in water to: 0.5 g/L of anhydrous citric acid and 0.4 g/L of anhydrous dibasic sodium phosphate in water
AMITRIPTYLINE HYDROCHLORIDE TABLETS	IMPURITIES/*Organic Impurities*	*Second Supplement to USP41–NF36*	8759	22-Feb-2019	1-Mar-2019	*NA*	*NA*	In *Analysis*: Change r_U = peak response of amitriptyline related compound A, amitriptyline related compound B, or nortriptyline hydrochloride from the *Sample solution r*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								r_S= peak response of amitriptyline related compound A, amitriptyline related compound B, or nortriptyline hydrochloride from the *Standard solution* to: r_U = peak response of amitriptyline related compound A, amitriptyline related compound B, or nortriptyline from the *Sample solution* r_S = peak response of amitriptyline related compound A, amitriptyline

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								related compound B, or nortriptyline from the *Standard solution*
MESNA	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*Second Supplement to USP41–NF36*	8904	22-Feb-2019	1-Mar-2019	*NA*	*NA*	In USP Mesna Related Compound A RS: Change 2-(Acetylthio)ethane-1-sulfonic acid. $C_4H_8O_4S_2$ 184.22 to: 2-(Acetylthio)ethane-1-sulfonic acid, potassium salt, crystal adduct with potassium chloride. $C_4H_7KO_4S_2$? KCl 296.86 AND In USP Mesna Related Compound B RS: Change 2,2?-Disulfanedi

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								ylbis(ethane-1-sulfonic acid). $C_4H_{10}O_6S_4$ 282.36 to: 2,2?-Disulfanediylbis(ethane-1-sulfonic acid), dipotassium salt, crystal adduct with sodium chloride. $C_4H_8K_2O_6S_4$? NaCl 416.98
SALMETEROL INHALATION POWDER	PERFORMANCE TESTS	*First Supplement to USP41–NF36*	Online	25-Jan-2019	1-Feb-2019	*NA*	*NA*	In the definition list in *Particle Size Distribution by Cascade Impaction/Analysis*: Change M_{r1} = molecular weight of salmeterol free base, 415.75 to: M_{r1} = molecular weight of salmeterol free base, 415.57

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								AND In the definition list in *Delivered-Dose Uniformity <601>/Analysis*: Change M_{r1} = molecular weight of salmeterol free base, 415.75 to: M_{r1} = molecular weight of salmeterol free base, 415.57
SALIX SPECIES BARK POWDER	INTRODUCTION	*USP42–NF37*	5189	25-Jan-2019	1-Feb-2019	*NA*	*NA*	Delete (This monograph is postponed indefinitely.)
LEFLUNOMIDE	IMPURITIES/*Organic Impurities/Procedure 2*	*USP41–NF36*	2353	25-Jan-2019	1-Feb-2019	*NA*	*NA*	Change *Standard solution*: 0.5 µg/mL of USP Leflunomide RS, from the *Standard solution* in *Mobile phase* to: *Standard stock*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								solution: Proceed as directed in the *Standard solution* in the *Assay*. *Standard solution*: 0.5 µg/mL of USP Leflunomide RS from the *Standard stock solution* in *Mobile phase*
SALIX SPECIES BARK DRY EXTRACT	INTRODUCTION	*USP42–NF37*	5187	25-Jan-2019	1-Feb-2019	*NA*	*NA*	Delete (This monograph is postponed indefinitely.)

Pagination

- First page « First
- Previous page ‹ Previous
- …
- Page 4
- Page 5
- Page 6
- Page 7
- Page 8

- Page 9
- Page 10
- Page 11
- Page 12
- …
- Next page Next ›
- Last page Last »